The Neuroscience and Animal Models Core (NAM) Core serves both as a resource for TMARC and as a scientific platform for translating clinical observations into appropriate in vitro and in vivo experimental models to study mechanisms of disease associated with methamphetamine (METH)/HIV-induced brain injury. The Core Resource Objectives include: 1) Provide transgenic (gp120 and ITat) animals that exhibit central nervous system (CNS) pathology associated with HIV;2) Provide the infrastructure for molecular analysis of the pathologic substrates in METH/HIV associated brain injury in HIV transgenic animals exposed to METH; furthermore, through linkage to the California NeuroAIDS Tissue Network (CNTN), the NAM Core will also access banked brain tissues that will support the translational aim of cross validating animal and human neuropathology, and finally, for in vitro studies we will provide experimental systems based on primary human neuroglial cultures, neuronal cell lines, and brain vascular smooth muscle cells;3) Foster translational research ideas by supporting Pilot studies and training in the field of experimental neuropathology for young investigators. The Core Scientific Objectives include: 1) Analyze the neuropathology induced by METH exposure in HIV transgenic animals, young and aged;2) Design neuropathologic analyses of HIV brains banked through the CNTN focused on aging, vascular and immune-mediated pathology associated with METH;3) Through support of Pilot studies, the NAM Core will generate preliminary data for future developmental projects within TMARC focused on issues such as chronic brain inflammation, metabolic and oxidative stress, aging and brain vascular pathology, METH effects on social cognition in HIV transgenic animals, and neuroprotective interventions.
Studies within the NAM Core will generate experimental neuropathology findings to be validated in the clinical setting. The long-term goals include validation of the neuropathologic correlates vis-a-vis clinical evaluations, development of projects targeting new mechanisms of disease and pioneering therapeutic interventions in the METH/HIV brain injury.
|Kamat, Rujvi; Doyle, Katie L; Iudicello, Jennifer E et al. (2016) Neurobehavioral Disturbances During Acute and Early HIV Infection. Cogn Behav Neurol 29:1-10|
|Noel, Richard J; Kaul, Marcus (2016) The 22nd Scientific Conference of the Society on Neuroimmune Pharmacology. J Neuroimmune Pharmacol 11 Suppl 1:S1-2|
|Soontornniyomkij, Virawudh; Umlauf, Anya; Soontornniyomkij, Benchawanna et al. (2016) Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults. J Neurovirol 22:650-660|
|Gianella, Sara; Letendre, Scott (2016) Cytomegalovirus and HIV: A Dangerous Pas de Deux. J Infect Dis 214 Suppl 2:S67-74|
|Kesby, James P; Markou, Athina; Semenova, Svetlana (2016) The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice. Neuropharmacology 109:205-15|
|Hoenigl, Martin; Little, Susan J (2016) How can we detect HIV during the acute or primary stage of infection? Expert Rev Mol Diagn 16:1049-1051|
|Bischoff-Grethe, Amanda; Connolly, Colm G; Jordan, Stephan J et al. (2016) Altered reward expectancy in individuals with recent methamphetamine dependence. J Psychopharmacol :|
|Brown, Gregory G; Jacobus, Joanna; McKenna, Benjamin (2016) Structural imaging for addiction medicine: From neurostructure to neuroplasticity. Prog Brain Res 224:105-27|
|Hoenigl, Martin; Chaillon, Antoine; Moore, David J et al. (2016) Clear Links Between Starting Methamphetamine and Increasing Sexual Risk Behavior: A Cohort Study Among Men Who Have Sex With Men. J Acquir Immune Defic Syndr 71:551-7|
|PÃ©rez-Santiago, JosuÃ©; Schrier, Rachel D; de Oliveira, Michelli F et al. (2016) Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection. J Neurovirol 22:191-200|
Showing the most recent 10 out of 108 publications